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spirin resistance is associated with a significant increase
in major adverse cardiovascular events.1,2 We have pre-
viously reported an insufficient antiplatelet effect of as-
pirin in most patients after coronary artery bypass
grafting (CABG).3 Nevertheless, the duration of aspirin resistance
after CABG remains unknown, and the suitability of available tools
to discriminate those with reduced response to aspirin is controver-
sial. This work determined the antiplatelet effect of aspirin at the
time of CABG and 6months later and examined the reliability of dif-
ferent methods for the diagnosis of aspirin resistance.
Materials and Methods
SUBJECTS AND DRUG ADMINISTRATION. This study was con-
ducted in agreement with the Declaration of Helsinki and was
approved by the institutional ethics committee. Twenty-five consec-
utive patients undergoing elective CABG for stable three-vessel dis-
ease were included. Informed consent was obtained from each
participant. Drugs affecting hemostasis had been discontinued at
least 10 days before surgery. Starting on day 1 after CABG, 100
mg aspirin (Aspirin 100; Bayer AG, Leverkusen, Germany) was
administered every morning.
MEASUREMENT OF PLATELET FUNCTION. The following param-
eters were determined: platelet counts (automated counting), arach-
idonic acid– (1mmol/L) or collagen (1mg/mL)–induced aggregation
(turbidimetry), thromboxane formation (radioimmunoassay), and
membrane closure times (platelet function analyzer PFA-100
(Dade Behring, Marburg, Germany), membrane coated with colla-
gen and epinephrine) before and on days 1, 5, and 10 after surgery,
as well as after a follow-up period of 6 months. Because thrombox-
ane formation is the pharmacologic target of aspirin, platelet func-
tion was investigated in vitro in the absence and presence of 30
mmol/L aspirin, a concentration comparable to or exceeding plasma
levels after oral aspirin treatment.4 Aspirin resistance during oral
antiplatelet treatment was defined as less than 90% inhibition of
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times less than 171 seconds.
STATISTICAL ANALYSIS. Data are shown as mean 6 SEM. Sta-
tistical analyses were performed by t test or analysis of variance, as
appropriate.
Results
Platelet counts decreased after extracorporeal circulation, from 251
6 30 cells/nL before CABG to 167 6 15 cells/nL at day 1 after
CABG, and subsequently increased to 256 6 13 cells/nL (day 5)
and 414 6 31 cells/nL (day 10). At 6-month follow-up, platelet
counts were comparable to values before surgery (268 6 45 cells/
nL).
Before CABG, arachidonic acid effectively induced platelet ag-
gregation in vitro and evoked a marked platelet thromboxane release
(Figure 1). Addition of aspirin in vitro significantly inhibited platelet
function. At day 1 after surgery, platelet function was blunted, prob-
ably as a result of extracorporeal circulation. On days 5 and 10 after
CABG, platelet aggregation was not significantly different from
values before surgery (despite oral aspirin therapy), and 30 mmol/L
aspirin failed to inhibit platelet function in vitro. Platelet function
was nearly completely inhibited, however, 6 months after CABG.
The results obtained after stimulation with collagen were similar
to those with arachidonic acid (not shown).
The PFA-100 method did not detect the blunted platelet function
at day 1 after CABG. Measurements obtained by this technique
remained unchanged at days 5 and 10 after CABG. Closure times
were nearly doubled (vs before surgery) at follow-up (Figure 2).
The incidences of aspirin resistance on day 5, on day 10, and 6
months after surgery were 93%, 86%, and 0%, respectively, in the
thromboxane assay and 100%, 75%, and 33% in the PFA-100
test. Moreover, thromboxane values were not significantly different
between those with and without response according to PFA-100 (18
6 5 ng/mL vs 34 6 14 ng/mL).
Discussion
These data show aspirin resistance early after CABG but a suffi-
cient antiplatelet effect 6 months thereafter. This pattern may ex-
plain why the elevated risk of graft thrombosis declines within
the first months after surgery.2 Another important finding is that
the thromboxane assay and PFA-100 test showed comparable re-
sults early after CABG, whereas these methods differently classi-
fied the responder status of a third of the patients at follow-up. In
accordance with thromboxane, arachidonic acid- and collagen-
induced aggregations showed near-complete platelet inhibition at
follow-up.
The observed differences between thromboxane and turbidime-
try on one hand and PFA-100 on the other hand may be explained
by variables unaffected by aspirin, such as von Willebrand factor,racic and Cardiovascular Surgery c Volume 135, Number 4 947
Brief CommunicationsFigure 1. Arachidonic acid (1 mmol/
L)—induced platelet aggregation (top)
and thromboxane formation (bottom) in
platelet-rich plasma of patients (n 5
25) before (control) and at indicated
times after coronary artery bypass
grafting (CABG). Measurements were
obtained in absence (black bars) or
presence (white bars) of aspirin (ASA)
in vitro (30 mmol/L). Asterisk indicates
P < .05 versus control values before
surgery; plus sign indicates P < .05
versus values without aspirin.which may outweigh platelet inhibition by aspirin in the PFA-100
method. Our results agree with the unfavorable correlation between
Figure 2. PFA-100 closure times with cartridges coated with col-
lagen and epinephrine. Whole blood from 25 patients was inves-
tigated before (control) and at indicated times after coronary
artery bypass grafting (CABG). Asterisk indicates P < .05 versus
control values before surgery. ASA, Aspirin.948 The Journal of Thoracic and Cardiovascular Surgery c ApPFA-100 and optical aggregation described in other study
populations.5
In conclusion, PFA-100 is a convenient bedside test. This
advantage, however, seems outweighed by its reduced accuracy in
comparison with turbidimetry and the criterion standard of
thromboxane.
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